68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
Lorlatinib Demonstrates “Fantastic” PFS Results in Advanced ALK+ NSCLC
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities
Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.
Fostering Multidisciplinary Care May Reduce Oncologist Workplace Burnout
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC
At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.
70 Malignancy Upgrade Rates of Discordant Breast Lesions
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
Chemoradiation Shows Responses Across Dose Levels in Anal Cancer
Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.
Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
ProstACT GLOBAL Results May Support “Open” Decisions in Metastatic CRPC
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Communication Between Leadership and Clinicians Improves Cancer Care
Leaders of a new cancer center, which is part of JFK University Medical Center, discuss how they can support frontline clinicians.
Highlighting “Trickle Down” Progress in Developing Rare Lymphoma Treatment
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
71 Beyond the Surface: Suspicious Nipple Lesions
Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC
Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.
Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC
Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.
FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC
Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer
Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Concurrent Chemoradiation May Improve LS-SCLC Prognosis
Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.
Cemsidomide Combo May Produce Responses in Multiple Myeloma
Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.
Perseverance Underscores Success in Rare Lymphoma Research
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma
Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.
Ileal Free Flap Urethroplasty May Remedy Devastated Bladder Outlet
A new type of robotic posterior surgery has been shown to be a treatment option for patients with devastated bladder outlets.
T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer
Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.
FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease
Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.
Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer
Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma
Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
Leveraging Beta and Alpha Emitters in Metastatic CRPC Management
Beta emitters such as lutetium Lu 177 rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Neurovascular Sparing during Radiation Reduces Incidence of ED in Prostate Cancer
The 1.5T Elekta Unity MR-Linac demonstrated lower rates of erectile dysfunction with neurovascular sparing vs without in patients with intermediate-risk prostate cancer.
!["Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US]," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fc33b85fa4b3edf9bdd0a6d37d81eee57f71a7348-1200x960.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US],\" according to the study authors.")
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
!["Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ffc2a0cb8c6d287fa539f7d61aad18a8752d347dc-1200x882.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option,\" according to the study authors.")
